Abstract
<jats:p> <jats:bold> <jats:italic>Background.</jats:italic> </jats:bold> Beta-adrenergic blockers, or beta-blockers (BBs), are a crucial class of medications. Given their extensive use in the management of cardiovascular diseases, regular analysis of BB availability and range in the pharmaceutical market is essential. </jats:p> <jats:p> <jats:bold> <jats:italic>Objective:</jats:italic> </jats:bold> To analyze the range of BBs available on the pharmaceutical market of the Republic of Uzbekistan, taking their quantitative composition, countries of origin, and dosage forms into account. </jats:p> <jats:p> <jats:bold> <jats:italic>Material and methods.</jats:italic> </jats:bold> The study utilized data from the State Register of medicines, medical devices and medical equipment approved for use in medical practice in the Republic of Uzbekistan. Methods employed included systematization, statistical and comparative analysis, and graphical representation of the results. </jats:p> <jats:p> <jats:bold> <jats:italic>Results.</jats:italic> </jats:bold> The Uzbek pharmaceutical market is dominated by metoprolol, bisoprolol, and nebivolol, with the majority of products are manufactured in the countries such as India, Russia, and Germany. Solid dosage forms, specifically tablets and capsules, are prevalent in this sector, which is consistent with the therapeutic use of this drug class. </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusion.</jats:italic> </jats:bold> <jats:bold/> The range of BBs in the pharmaceutical market of Uzbekistan is extensive in terms of international nonproprietary names, trade names, and manufacturing origins. This reflects consistent demand and the clinical importance of this drug group in the management of cardiovascular conditions. The findings can be used to further improve the pharmaceutical supply system. </jats:p>